VIDEO: Updates in immune, cellular therapies in acute myeloid leukemia
Click Here to Manage Email Alerts
In this video, Naval Daver, MD, discusses a presentation on updates in immune and cellular therapy in acute myeloid leukemia from Society of Hematologic Oncology Annual Meeting.
Daver, professor and director of the Leukemia Research Alliance Program in the department of leukemia at The University of Texas MD Anderson Cancer Center, said that Marion Subklewe, MD, of Ludwig-Maximilians-University of Munich in Munich, Germany, discussed new data on the use of bispecific antibodies, cellular therapies, antibody-drug conjugates — including gemtuzumab ozogamicin (Mylotarg, Pfizer) and pivekimab sunirine (IMGN632, ImmunoGen) — natural killer (NK)-based cell therapies, chimeric antigen receptor T-cell therapies and more in patients with AML.
“Hopefully in the near future, some of these will emerge as effective outcomes and options for our patients with acute myeloid leukemia,” Daver said.
Reference:
- Subklewe M. Immune/cellular therapy in AML. Presented at: Society of Hematologic Oncology Annual Meeting; Sept. 4-7, 2024; Houston.
Collapse
Healio Interviews
Click Here to Manage Email Alerts